Ne-Hodgkinovy lymfomy

Recommendations for initial evaluation, staging, and response assessment of Hodgkin and Non-Hodgkin lymphoma: the Lugano classification

Role of imaging in the staging and response assessment of lymphoma: consensus of the International conference on Malignant lymphomas imaging working group

How I treat Burkitt lymphoma in adults

Indications for hematopoietic stem cell transplantation in patients with follicular lymphoma: a consensus project of the EBMT-Lymphoma Working Party

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

Rituximab Maintenance Compared With Observation After Brief First-Line R-FND Chemoimmunotherapy With Rituximab Consolidation in Patients Age Older Than 60 Years With Advanced Follicular Lymphoma: A phase III Randomized Study by the Fondazione Italiana Linfomi

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

The BRAF V600E mutation in hairy cell leukemia and other mature B cell neoplasms

Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era

Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in rituximab era

Management of post-transplant lymphoproliferative disorder in adult solid organ transplant recipients - BCSH and BTS guidelines

Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients – BCSH and BTS guidelines

High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma: a randomised phase 2 trial

Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with standard weekly x4 schedule.

Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL).

Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Group B.

Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin´s lymphoma: a randomized phase II trial of the Minnie Pearl Cancer Research Network.

Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin´s lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial.

Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) in patients with relapsed and refraktory follicular and mantle cell lymphomas – results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG).

Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study

Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-Cell lymphoma: a study by the groupe d´etude des lymphomes de l´adulte

Revised response criteria for malignant lymphoma

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network

Immunochemotherapy with Rituximab and Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the german low grade lymphoma study group (GLSG)

Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study

Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study

Randomised comparison of cladribine alone or in combination with cyclophosphamide, and cyclophosphamide, vincristine and prednisone in previously untreated low-grade B-cell non-Hodgkin lymphoma patients (final report of the Polish Lymphoma Research Group)

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

Practice guidelines for the management of extranodal non-Hodgkin´s lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian society of hematology, the Italian society of experimental hematology and the Italian group for bone marrow transplantation

CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International (MInT) Study Group